Abstract
The biological response to cannabinoid agonist begins when the agonist-bound receptor activates G-protein Gα subunits, thus initiating a cascade of signal transduction pathways. For this reason, information about cannabinoid receptors/G-protein coupling is critical to understand both the acute and chronic actions of cannabinoids. This review focuses on these mechanisms, predominantly examining the ability of cannabinoid agonists to activate G-proteins in brain with agonist-stimulated [35S]guanylyl-5′-O-(γ-thio)-triphosphate ([35S]GTPγS) binding. Acute efficacies of cannabinoid agonists at the level of G-protein activation depend not only on the ability of the agonist to induce a high affinity state in Gα for GTP, but also to induce a low affinity for GDP. When several agonists are compared, it is clear that cannabinoid agonists differ considerably in their efficacy. Both WIN 55212-2 and levonantradol are full agonists, while Δ9-tetrahydrocannabinol is a weak partial agonist. Of interest, anandamide and its stable analog methanandamide are partial agonists. Chronic treatment in vivo with cannabinoids produces significant tolerance to the physiological and behavioral effects of these drugs, and several studies have shown that this is accompanied by a significant loss in the ability of cannabinoid receptors to couple to G-proteins in brain. These effects vary across different brain regions and are usually (but not always) accompanied by loss of cannabinoid receptor binding. Although the relationship between cannabinoid receptor desensitization and tolerance has not yet been established, these mechanisms may represent events that lead to a loss of cannabinoid agonist response and development of tolerance.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Howlett AC. Inhibition of neuroblastoma adenylyl cyclase by cannabinoid and nantradol compounds. Life Sci. 1984;35:1803-1810.
Howlett AC, Fleming RM. Cannabinoid inhibition of adenylate cyclase: pharmacology of the response in neuroblastoma cell membranes. Mol Pharmacol. 1984;26:532-538.
Howlett AC. Cannabinoid inhibition of adenylate cyclase: biochemistry of the response in neuroblastoma cell membranes. Mol Pharmacol. 1985;27:429-436.
Howlett AC, Qualy JM, Khachatrian LL. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol Pharmacol. 1986;29:307-313.
Devane WA, Dysarz FAI, Johnson MR, Melvin LS, Howlett AC. Determination and charac-terization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988;34:605-613.
Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci. 1991;11:563-583.
Matsuda LA, Lolait SJ, Brownstein MJ, Young AL, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346:561-564.
Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61-65.
Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946-1949.
Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglycer-ide, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 1995;50:83-90.
Houston DB, Howlett AC. Solubilization of the cannabinoid receptor from rat brain and its functional interaction with guanine nucleotide-binding proteins. Mol Pharmacol. 1993;43:17-22.
Mukhopadhyay S, Howlett AC. Chemically distinct ligands promote differential CB1 cannabi-noid receptor-Gi protein interactions. Mol Pharmacol. 2005;67:2016-2024.
Selley DE, Stark S, Sim LJ, Childers SR. Cannabinoid receptor stimulation of guanosine-5′-O-(3-[35S]thio)triphosphate binding in rat brain membranes. Life Sci. 1996;59:659-668.
Kurose H, Katada T, Haga T, Haga K, Ichiyama A, Ui M. Functional interaction of purified muscarinic receptors with purified inhibitory guanine nucleotide regulatory proteins reconstituted in phospholipid vesicles. J Biol Chem. 1986;261:6423-6428.
Florio VA, Sternweiss PC. Mechanisms of muscarinic receptor action on Go in reconstituted phospholipid vesicles. J Biol Chem. 1989;264:3909-3915.
Asano T, Pedersen SE, Scott CW, Ross EM. Reconstitution of catecholamine-stimulated bind-ing of guanosine 5′-O-(3-thiotriphosphate) to the stimulatory GTP-binding protein of ade-nylate cyclase. Biochemistry. 1984;23:5460-5467.
Hilf G, Gierschik P, Jakobs KH. Muscarinic acetylcholine receptor-stimulated binding of guanosine 5′-O-(3-thiotriphosphate) to guanine-nucleotide-binding proteins in cardiac mem-branes. Eur J Biochem. 1989;186:725-731.
Lorenzen A, Fuss M, Vogt H, Schwabe U. Measurement of guanine nucleotide-binding pro-tein activation by A1 adenosine receptor agonists in bovine brain membranes: stimulation of guanosine-5′-O-(3-[35S]thio)triphosphate binding. Mol Pharmacol. 1993;44:115-123.
Lazareno S, Farries T, Birdsall NJM. Pharmacological characterization of guanine nucleotide exchange reactions in membranes from CHO cells stably transfected with human muscarinic receptors M1-M4. Life Sci. 1993;52:449-456.
Levy FO, Zhu X, Kaumann AJ, Birnbaumer L. Efficacy of β1-adrenergic receptors is lower than that of β2-adrenergic receptors. Proc Natl Acad Sci USA. 1993;90:10798-10802.
Birnbaumer L, Levy FO, Zhu X, Kaumann AJ. Studies on the intrinsic activity (efficacy) of human adrenergic receptors. Tex Heart Inst J. 1994;21:16-21.
Breivogel CS, Selley DE, Childers SR. Acute and chronic effects of opioids on delta and mu receptor activation of G-proteins in NG108-15 and SK-N-SH cell membranes. J Neurochem. 1997;68:1462-1472.
Sim LJ, Selley DE, Childers SR. In vitro autoradiography of receptor-activated G-proteins in rat brain by agonist-stimulated guanylyl 5′-[γ-[35S]thio]-triphosphate binding. Proc Natl Acad Sci USA. 1995;92:7242-7246.
Breivogel CS, Selley DE, Childers SR. Cannabinoid receptor agonist efficacy for stimulating [35S]GTPγS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity. J Biol Chem. 1998;273:16865-16873.
Kuster J, Stevenson J, Ward S, D’Ambra T, Haycock D. Aminoalkylindole binding in rat cer-ebellum: selective displacement by natural and synthetic cannabinoids. J Pharmacol Exp Ther. 1993;264:1352-1363.
Sim LJ, Selley DE, Xiao R, Childers SR. Differences in G-protein activation by mu and delta opioid, and cannabinoid, receptors in rat striatum. Eur J Pharmacol. 1996;307:97-105.
Breivogel CS, Sim LJ, Childers SR. Regional differences in cannabinoid receptor/G-protein coupling in rat brain. J Pharmacol Exp Ther. 1997;282:1632-1642.
Selley DE, Sim LJ, Xiao R, Liu Q, Childers SR. Mu opioid receptor-stimulated [35S]GTPγS binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy. Mol Pharmacol. 1997;51:87-96.
Burkey TH, Quock RM, Consroe P, et al. Relative efficacies of cannabinoid CB1 receptor ago-nists in the mouse brain. Eur J Pharmacol. 1997;336:295-298.
Sim LJ, Hampson RE, Deadwyler SA, Childers SR. Effects of chronic treatment with Δ9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPγS autoradiography in rat brain. J Neurosci. 1996;16:8057-8066.
Childers SR, Sexton T, Roy MB. Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochem Pharmacol. 1994;47:711-715.
Mackie K, Devane WA, Hille B. Anandamide, an endogenous cannabinoid, inhibits calcium cur-rents as a partial agonist in N18 neuroblastoma cells. Mol Pharmacol. 1993;44:498-503.
Shen M, Piser TM, Seybold VS, Thayer SA. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci. 1996;16:4322-4334.
Landsman RS, Burkey TH, Consroe P, Roeske WR, Yamamura HI. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur J Pharmacol. 1997;334:R1-R2.
Felder CC, Joyce KE, Briley EM, et al. Comparison of the pharmacology and signal transduc-tion of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol. 1995;48:443-450.
Pacheco M, Ward SJ, Childers SR. Identification of cannabinoid receptors in cultures of rat cerebel-lar granule cells. Brain Res. 1993;603:102-110.
Bidaut-Russell M, Devane WA, Howlett AC. Cannabinoid receptors and modulation of cyclic AMP accumulation in the rat brain. J Neurochem. 1990;55:21-26.
Glass M, Felder CC. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 recep-tor. J Neurosci. 1997;17:5327-5333.
Caulfield MP, Brown DA. Cannabinoid receptor agonists inhibit Ca currents in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br J Pharmacol. 1992;106:231-232.
Mackie K, Lai Y, Westenbroek R, Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci. 1995;15:6552-6561.
Diana MA, Levenes C, Mackie K, Marty A. Short-term retrograde inhibition of GABAergic synaptic currents in rat Purkinje cells is mediated by endogenous cannabinoids. J Neurosci. 2002;22:200-208.
Deadwyler SA, Heyser CJ, Hampson RE. Complete adaptation to the memory disruptive effects of delta-9-THC following 35 days of exposure. Neurosci Res Commun. 1995;17:9-18.
Abood ME, Sauss C, Fan F, Tilton CL, Martin BR. Development of behavioral tolerance to Δ9-THC without alteration of cannabinoid receptor binding or mRNA levels in whole brain. Pharmacol Biochem Behav. 1993;46:575-579.
Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction. 1996;91:1585-1614.
Fan F, Tao Q, Abood ME, Martin BR. Cannabinoid receptor down-regulation without altera-tion of the inhibitory effect of CP 55,940 on adenylyl cyclase in the cerebellum of CP 55,940-tolerant mice. Brain Res. 1996;706:13-20.
Rodríguez de Fonseca F, Gorriti MA, Fernandez-Ruiz JJ, Palomo T, Ramos JA. Downregulation of rat brain cannabinoid binding sites after chronic Δ9-tetrahydrocannabinol treatment. Pharmacol Biochem Behav. 1994;47:33-40.
Romero J, Garciá L, Fernández-Ruiz JJ, Cebeira M, Ramos JA. Changes in rat brain cannabi-noid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to Δ9-tetrahydrocannabinol. Pharmacol Biochem Behav. 1995;51:731-737.
Coutts AA, Anavi-Goffer S, Ross RA, et al. Agonist-induced internalization and trafficking of cannabinoid CB1 receptors in hippocampal neurons. J Neurosci. 2001;21:2425-2433.
Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Vogt LJ, Sim-Selley LJ. Chronic Δ9-tetrahydrocannabinol produces a time-dependent loss of cannabinoid receptors and can-nabinoid receptor-activated G-proteins in rat brain. J Neurochem. 1999;73:2447-2459.
Breivogel CS, Scates SM, Beletskaya IO, Lowery OB, Aceto MD, Martin BR. The effects of delta9-tetrahydrocannabinol physical dependence on brain cannabinoid receptors. Eur J Pharmacol. 2003;459:139-150.
Sim-Selley LJ, Martin BR. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice. J Pharmacol Exp Ther. 2002;303:36-44.
Corchero J, Romero J, Berrendero F, et al. Time-dependent differences of repeated administration with Delta9-tetrahydrocannabinol in proenkephalin and cannabinoid receptor gene expression and G-protein activation by mu-opioid and CB1-cannabinoid receptors in the caudate-putamen. Brain Res Mol Brain Res. 1999;67:148-157.
Rubino T, Vigano D, Costa B, Colleoni M, Parolaro D. Loss of cannabinoid-stimulated gua-nosine 5′-O-(3-[(35)S]thiotriphosphate) binding without receptor down-regulation in brain regions of anandamide-tolerant rats. J Neurochem. 2000;75:2478-2484.
Sim-Selley LJ. Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol. 2003;15:91-119.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Childers, S.R. (2008). Activation of G-Proteins in Brain by Endogenous and Exogenous Cannabinoids. In: Rapaka, R.S., Sadée, W. (eds) Drug Addiction. Springer, New York, NY. https://doi.org/10.1007/978-0-387-76678-2_42
Download citation
DOI: https://doi.org/10.1007/978-0-387-76678-2_42
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-76677-5
Online ISBN: 978-0-387-76678-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)